Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 4,300 shares, a decrease of 53.8% from the September 30th total of 9,300 shares. Based on an average daily volume of 9,100 shares, the days-to-cover ratio is currently 0.5 days.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of Adlai Nortye in a report on Friday, October 18th.
Check Out Our Latest Report on ANL
Adlai Nortye Stock Down 0.7 %
About Adlai Nortye
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Featured Articles
- Five stocks we like better than Adlai Nortye
- What is a Low P/E Ratio and What Does it Tell Investors?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- With Risk Tolerance, One Size Does Not Fit All
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Investing in Commodities: What Are They? How to Invest in Them
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.